|
Characteristics
| |
RMSTb (95%CI)
|
HRc (95%CI)
|
P valuea
|
Interaction p
|
|---|
|
Non-chemotherapy
|
Chemotherapy
|
|---|
|
Total
|
–
|
55.2 (52.8–57.0)
|
56.9 (55.2–58.0)
|
0.612 (0.321–1.168)
|
0.132
|
–
|
|
Sex
|
Male
|
55.0 (51.1–57.2)
|
56.7 (54.3–58.2)
|
0.636 (0.269–1.502)
|
0.298
|
0.887
|
|
Female
|
55.4 (51.1–57.7)
|
57.2 (54.5–58.6)
|
0.599 (0.225–1.599)
|
0.301
| |
|
Age (years)
|
≤55
|
52.0 (40.0–57.2)
|
57.5 (54.0–58.9)
|
0.262 (0.062–1.107)
|
0.050
|
0.179
|
|
56–60
|
56.0 (38.7–59.5)
|
57.0 (52.2–58.9)
|
0.849 (0.095–7.617)
|
0.884
| |
|
61–65
|
55.4 (43.1–58.8)
|
55.7 (51.1–57.8)
|
0.882 (0.176–4.421)
|
0.879
| |
|
66–70
|
52.9 (45.9–56.5)
|
–
|
0.015 (0.001–10.71)
|
0.014
| |
|
> 70
|
56.8 (53.0–58.5)
|
54.9 (47.8–58.0)
|
1.569 (0.442–5.569)
|
0.482
| |
|
Size (cm)
|
≤5.0
|
55.6 (51.7–57.6)
|
56.3 (53.7–57.9)
|
0.849 (0.341–2.114)
|
0.724
|
0.254
|
|
> 5.0
|
53.7 (50.5–55.8)
|
56.3 (54.5–57.5)
|
0.452 (0.178–1.146)
|
0.086
| |
|
Differentiation
|
Well-moderate
|
53.9 (52.0–55.4)
|
56.3 (55.2–57.2)
|
0.621 (0.310–1.246)
|
0.175
|
0.990
|
|
Poor
|
52.0 (43.2–56.6)
|
54.7 (46.8–57.8)
|
0.594 (0.099–3.561)
|
0.564
| |
|
T category
|
3
|
56.4 (53.7–58.0)
|
57.6 (55.5–58.6)
|
0.581 (0.116–2.907)
|
0.504
|
0.746
|
|
4
|
51.8 (49.2–54.0)
|
55.6 (54.2–56.8)
|
0.575 (0.284–1.165)
|
0.119
| |
|
CEAd (ng/mL)
|
< 5
|
54.6 (51.9–56.4)
|
56.7 (55.3–57.8)
|
0.606 (0.219–1.675)
|
0.329
|
0.522
|
|
≥5
|
53.5 (50.1–55.7)
|
55.1 (52.8–56.8)
|
0.793 (0.305–2.061)
|
0.633
| |
|
Examined lymph nodes
|
< 12
|
52.0 (47.5–54.9)
|
53.6 (50.2–55.6)
|
0.626 (0.216–1.816)
|
0.383
|
0.949
|
|
≥12
|
54.5 (52.3–56.0)
|
57.1 (55.9–57.9)
|
0.670 (0.293–1.534)
|
0.340
| |
|
PLRe
|
≤130
|
56.0 (53.6–57.6)
|
56.0 (54.3–57.2)
|
1.093 (0.328–3.647)
|
0.885
|
0.276
|
|
> 130
|
51.3 (47.8–53.7)
|
56.5 (54.8–57.7)
|
0.464 (0.211–1.024)
|
0.051
| |
- a P value of the log-rank test
- b RMST: the restricted mean survival time
- c HR: Hazard Ratio, chemotherapy patients vs. non-chemotherapy patients
- d CEA: carcinoembryonic antigen
- e PLR: platelet to lymphocyte ratio
